Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis

Freeman, Scott R.; Drake, Amanda L.; Heilig, Lauren F.; Graber, Marla M.; McNealy, Kristie; Schilling, Lisa M.; Dellavalle, Robert P.

doi:10.1093/jnci/djj412

Cited by 74 publications

(47 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data for incident melanoma cases of four trials [27,28,31,32] were reported in Freeman et al [33]. Regarding the eight fluvastatin RCTs, the number of incident melanoma cases was reported in one summary report [24].…”

Section: Search Resultsmentioning

confidence: 99%

“…Three previously published meta-analyses have also examined the association between statin use and melanoma risk [33,41,42]. However, in these studies the number of RCTs included in the analysis ranged from 5 [41] to 12 [33], involving up to 39,426 participants [33].…”

Section: Discussionmentioning

confidence: 99%

“…However, in these studies the number of RCTs included in the analysis ranged from 5 [41] to 12 [33], involving up to 39,426 participants [33]. In our analysis, 16 RCTs involving 62,568 individuals were included, giving greater power to evaluate the relationship.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials

Bonovas

Nikolopoulos

Filioussi³

et al. 2009

Eur J Epidemiol

View full text Add to dashboard Cite

A growing body of literature suggests that statins may have a chemopreventive potential against melanoma through pleiotropic anti-inflammatory, immunomodulatory, and antiangiogenesis mechanisms. Our aim was to examine this association through a detailed meta-analysis of randomized controlled trials (RCTs). A comprehensive search for trials published up to June 2009 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk estimates (RR) and 95% confidence intervals (CIs) were calculated using the fixed- and the random-effects models. Subgroup and sensitivity analyses were also conducted. Sixteen RCTs of statins for cardiovascular outcomes, involving 62,568 individuals with a mean age of 60 years and an average follow-up of nearly 4.7 years, contributed to the analysis. We found no evidence of publication bias (P = 0.47) or heterogeneity among the studies (P = 0.25). Statin use did not significantly affect the risk of developing melanoma assuming either a fixed- (RR = 0.92, 95% CI: 0.67-1.26), or a random-effects model (RR = 0.92, 95% CI: 0.62-1.36). This neutral effect was further supported by the results of subgroup and sensitivity analyses. Our findings do not support a protective effect of statins against melanoma.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials

Bonovas

Nikolopoulos

Filioussi³

et al. 2009

Eur J Epidemiol

View full text Add to dashboard Cite

show abstract

“…Statins were not documented to prevent or affect hematological malignancies (51) , or melanoma (a type of skin malignancy) (52).…”

Section: Evidence Against a Low Cholesterol Being Associated With Cancermentioning

confidence: 99%

Understanding cholesterol: high is bad but too low may also be risky – is low cholesterol associated with cancer?

Simko¹,

Гинтер²

2014

BLL

View full text Add to dashboard Cite

Cholesterol (CH) is a vital component of cell membranes and of their function. It is entirely justifi ed to warn against haphazard aggressive CH lowering, especially now, when more effective CH-modifying medications are entering the market. Enormous success in lowering the human toll of atherosclerosis and cardiovascular disease (CVD) by treating abnormally elevated lipids may be off set by the therapeutic risk. There are warning reports that low cholesterol is associated with malignity. There is a pressing need to evaluate all reports related to the risk of low CH body stores. New cholesterol management guidelines presented by American professional cardiology societies in November 2013 have reinforced the need to critically evaluate the management with statins and with other CH lowering medications (Tab. 1, Fig. 3, Ref. 58). Text in PDF www.elis.sk.

show abstract

“…As the number of incident melanoma cases was low, a specific study to address the role of statins in preventing melanoma would need to be designed, with the required power to provide answers (Freeman et al, 2006).…”

Section: Statinsmentioning

confidence: 99%

Development of monoclonal antibodies for the identification of novel invasion associated targets in human cancer

O'sullivan¹

2008

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis

Abstract: These findings do not validate the possibility that statins or fibrates prevent melanoma.

Cited by 74 publications

References 56 publications

Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials

Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials

Understanding cholesterol: high is bad but too low may also be risky – is low cholesterol associated with cancer?

Development of monoclonal antibodies for the identification of novel invasion associated targets in human cancer

Contact Info

Product

Resources

About